Literature DB >> 26861005

Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds.

Michele Tonelli1, Elena Cichero.   

Abstract

In this review we discuss drug design strategies directed to the development of potential anti-influenza A(H1N1) inhibitors of M2 ion channel, neuraminidase (NA), hemagglutinin (HA) and RNA-dependent RNA-polymerase complex (RdRp) major targets, following temporal chronology of their findings. Besides searching for new chemotypes, eventually active against new targets of influenza A (H1N1), the design of optimized analogues of proven drugs is largely pursued, taking into account the emerging insight into the mechanisms of resistance to existing antivirals. Computational studies are also summarized, in order to highlight the structural requirements for further chemical optimizations.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26861005     DOI： 10.2174/0929867323666160210124930

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  9 in total

1.  Methods of Synthesis and Antiviral Activity of New 4-Alkyl-3-Nitro-1,4-Dihydroazolo[5,1-c][1,2,4]Triazin-4-ols.

Authors:  Roman A Drokin; Dmitrii V Tiufiakov; Egor K Voinkov; Pavel A Slepukhin; Evgeny N Ulomsky; Yana L Esaulkova; Alexandrina S Volobueva; Kristina S Lantseva; Mariya A Misyurina; Vladimir V Zarubaev; Vladimir L Rusinov
Journal:  Chem Heterocycl Compd (N Y)       Date:  2021-05-12       Impact factor: 1.490

2.  Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.

Authors:  Nan-Hung Hsieh; Yi-Jun Lin; Ying-Fei Yang; Chung-Min Liao
Journal:  Infect Drug Resist       Date:  2017-07-20       Impact factor: 4.003

3.  In vitro anti-influenza virus effect of total flavonoid from Trollius ledebouri Reichb.

Authors:  Yongping Liu; Jiming Tong; Ying Tong; Ping Li; Xiaolan Cui; Hongbao Cao
Journal:  J Int Med Res       Date:  2018-02-14       Impact factor: 1.671

4.  Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.

Authors:  Michele Tonelli; Lieve Naesens; Sabrina Gazzarrini; Matteo Santucci; Elena Cichero; Bruno Tasso; Anna Moroni; Maria Paola Costi; Roberta Loddo
Journal:  Eur J Med Chem       Date:  2017-04-27       Impact factor: 6.514

Review 5.  Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials.

Authors:  Barbara Rath; Tim Conrad; Puja Myles; Maren Alchikh; Xiaolin Ma; Christian Hoppe; Franziska Tief; Xi Chen; Patrick Obermeier; Bron Kisler; Brunhilde Schweiger
Journal:  Expert Rev Anti Infect Ther       Date:  2017-05-12       Impact factor: 5.091

6.  Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).

Authors:  Valeria Francesconi; Luca Giovannini; Matteo Santucci; Elena Cichero; Maria Paola Costi; Lieve Naesens; Fabrizio Giordanetto; Michele Tonelli
Journal:  Eur J Med Chem       Date:  2018-06-02       Impact factor: 6.514

7.  The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo.

Authors:  Hui-Jun Dong; Zhao-Hua Wang; Wen Meng; Cui-Cui Li; Yan-Xin Hu; Lei Zhou; Xiao-Jia Wang
Journal:  Viruses       Date:  2018-11-01       Impact factor: 5.048

8.  Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Authors:  Prabhat Pratap Singh Tomar; Miriam Krugliak; Isaiah T Arkin
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23

Review 9.  RdRp (RNA-dependent RNA polymerase): A key target providing anti-virals for the management of various viral diseases.

Authors:  Shelly Pathania; Ravindra K Rawal; Pankaj Kumar Singh
Journal:  J Mol Struct       Date:  2021-10-17       Impact factor: 3.196
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.